BR9608894A - Produtos extracelulares abundantes e processos para suas producões e usos - Google Patents

Produtos extracelulares abundantes e processos para suas producões e usos

Info

Publication number
BR9608894A
BR9608894A BR9608894-0A BR9608894A BR9608894A BR 9608894 A BR9608894 A BR 9608894A BR 9608894 A BR9608894 A BR 9608894A BR 9608894 A BR9608894 A BR 9608894A
Authority
BR
Brazil
Prior art keywords
extracellular products
vaccines
abundant
processes
abundant extracellular
Prior art date
Application number
BR9608894-0A
Other languages
English (en)
Inventor
Marcus A Horwitz
Gunter Harth
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/447,398 external-priority patent/US6761894B1/en
Application filed by Univ California filed Critical Univ California
Publication of BR9608894A publication Critical patent/BR9608894A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

''PRODUTOS EXTRACELULARES ABUNDANTES E PROCESSOS PARA SUA PRODUçãO E USO" Vacinas à base de uma ou mais combinações de produtos extracelulares abundantes de agentes patogênicos e processos para os seus usos e produções são apresentadas. Os produtos extracelulares abundantes predominantes de um agente patogên ico alvo são selecionados independentemente das suas imunogenicidade moleculares absolutas e usados como vacinas para estimular uma resposta imunoprotetora em hospedeiros mamíferos contra a subsequente infecção pelo agente patogênico alvo. Os produtos extracelulares abundantes predominantes podem ser caracterizados e distinguidos pelo seus aminoácidos N-terminais respectivos, aminoácidos ou sequênciasde DNA. Como as vacinas podem compreender diferentes combinações dos produtos extracelulares das suas subunidades ou codificação de ácidos nucleicos, uma ampla variedade de composições imunoterapêuticas eficazes são fornecidas pela presente invenção. Além dos agentes infecciosos, as vacinas assim produzidas podem ser usadas para estimular uma resposta imunoeficaz contra agentes patogênicos intracelulares e em particular o Mycobacterium tuberculosis.
BR9608894-0A 1995-05-23 1996-05-23 Produtos extracelulares abundantes e processos para suas producões e usos BR9608894A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/447,398 US6761894B1 (en) 1993-11-23 1995-05-23 Abundant extracellular products and methods for their production and use
US54592695A 1995-10-20 1995-10-20
US55114995A 1995-10-31 1995-10-31
US56835795A 1995-12-06 1995-12-06
PCT/US1996/007781 WO1996037219A1 (en) 1995-05-23 1996-05-23 Abundant extracellular products and methods for their production and use

Publications (1)

Publication Number Publication Date
BR9608894A true BR9608894A (pt) 1999-12-07

Family

ID=27503944

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608894-0A BR9608894A (pt) 1995-05-23 1996-05-23 Produtos extracelulares abundantes e processos para suas producões e usos

Country Status (7)

Country Link
EP (1) EP0828510A1 (pt)
JP (1) JPH11506320A (pt)
AU (1) AU6024596A (pt)
BR (1) BR9608894A (pt)
CA (1) CA2222000C (pt)
NZ (1) NZ309945A (pt)
WO (1) WO1996037219A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
CA2278116A1 (en) * 1997-01-21 1998-07-23 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
EP1449922B1 (en) * 1997-04-02 2007-08-15 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
WO1999002559A1 (en) * 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
NZ504951A (en) * 1997-11-10 2001-06-29 Statens Seruminstitut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
GB0003082D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Vaccine
BR0111834A (pt) * 2000-06-22 2003-07-08 American Cyanamid Co Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
WO2013091004A1 (en) * 2011-12-22 2013-06-27 The University Of Sydney Prevention and treatment of mycobacterium infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108745B1 (en) * 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
WO1995014713A2 (en) * 1993-11-23 1995-06-01 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
WO1996005223A1 (en) * 1994-08-12 1996-02-22 The Regents Of The University Of California Abundant extracellular products and methods for their production and use

Also Published As

Publication number Publication date
MX9709053A (es) 1998-10-31
CA2222000A1 (en) 1996-11-28
CA2222000C (en) 2012-03-20
EP0828510A1 (en) 1998-03-18
NZ309945A (en) 2001-04-27
JPH11506320A (ja) 1999-06-08
WO1996037219A1 (en) 1996-11-28
AU6024596A (en) 1996-12-11

Similar Documents

Publication Publication Date Title
BR9608894A (pt) Produtos extracelulares abundantes e processos para suas producões e usos
BR9408135A (pt) Produtos extra-celulares abundantes e processos para sua produção e uso
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
NO20070618L (no) Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
DK0495896T3 (da) Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
PT914437E (pt) Identificacao e clonagem de um antigenio micobacteriano correspondente a uma hemaglutinina de ligacao a heparina
AU2529095A (en) Vaccine against mycobacterial infections
CA2095534A1 (en) Avirulent microbes and uses therefor
DK0791063T3 (da) Bærerprotein med adjuvansvirkning, immunogent kompleks omfattende det, fremgangsmåde til fremstilling deraf, nukleotidsekvens og vaccine
ATE169958T1 (de) Herstellung der p1 proteine und impfstoffe gegen gonorrhöe
AU6029898A (en) Abundant extracellular products and methods for their production and use
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
BR0002602A (pt) Vacina viva atenuada, uso de uma bactéria viva atenuada, e, processo para a preparação de uma vacina
ATE121423T1 (de) Impfstoff, geeignet für die bekämpfung von bordetella pertussis.
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
PT87001A (pt) Processo para a preparacao de uma vacina contra a disenteria suina e fins analogos
KR900701831A (ko) 열대열 말라리아 원충의 분열소체 표면 항원의 대립형질 변이주
WO2024186780A3 (en) Compositions and methods for treating and preventing crimean congo hemorrhagic fever virus
NZ510063A (en) Abundant extracellular products and methods for their production and use
MX9701103A (es) Productos extracelulares abundantes y metodos para su produccion y uso.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]